Deutsch, E <br/><br/>
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.  [electronic resource] 

 -  British journal of cancer  Nov 2004 
 - 1735-41 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0007-0920 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6602190  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides<br/>Cell Proliferation--drug effects<br/>DNA-Activated Protein Kinase<br/>DNA-Binding Proteins--antagonists & inhibitors<br/>Drug Resistance, Neoplasm<br/>Enzyme Inhibitors--therapeutic use<br/>Fusion Proteins, bcr-abl<br/>Gene Expression Regulation, Leukemic<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Erythroblastic, Acute--drug therapy<br/>Mice<br/>Mice, Nude<br/>Neoplasm Recurrence, Local--drug therapy<br/>Nuclear Proteins<br/>Phosphorylation<br/>Piperazines--pharmacology<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins--metabolism<br/>Proto-Oncogene Proteins c-akt<br/>Pyrimidines--pharmacology<br/>Tumor Cells, Cultured<br/>Tyrphostins--therapeutic use